Chonluten Peptide

Bronchial mucosa tripeptide bioregulator that modulates respiratory immune responses. Research shows it normalizes local IgA secretion, mucosal T-cell populations, and cytokine balance in the bronchial associated lymphoid tissue (BALT).

Chonluten is a synthetic bioregulatory tripeptide with the amino acid sequence Thr-Glu-Asp (T-E-D), molecular formula C₁₅H₂₄N₄O₁₀, molecular weight 420.37 g/mol, and CAS number 164365-43-3. It was developed at the Saint Petersburg Institute of Bioregulation and Gerontology under the direction of Professor Vladimir Khavinson as part of the Khavinson short peptide family, derived from chromatographic fractionation of bronchial mucosal tissue extracts. Chonluten is classified as a tissue-specific bioregulator (cytomedin) that has been investigated in preclinical models for its effects on bronchial epithelium, alveolar macrophages, and mucosal immune signaling.

Within the Khavinson peptide framework, Chonluten represents the bronchopulmonary branch — analogous to how Epithalon (Ala-Glu-Asp-Gly) targets the pineal gland, Vilon (Lys-Glu) modulates thymic activity, and Cortagen (Ala-Glu-Asp-Pro) is associated with cerebral cortex tissue. The compound has been the subject of multiple Russian-language publications and an expanding international literature describing its association with restoration of mucociliary epithelium, normalization of secretory IgA production, and modulation of inflammatory cytokine cascades in aged or chemically injured respiratory tissue models. Research suggests Chonluten functions at picomolar to nanomolar concentrations, consistent with the broader pharmacology of short regulatory peptides that act as putative transcriptional modulators rather than classical receptor agonists.

Chonluten is distinguished from the related peptide Bronchogen (Ala-Glu-Asp-Leu), another bronchopulmonary bioregulator, by its tripeptide structure and a research profile emphasizing alveolar macrophage function and Clara cell (club cell) restoration. Where Bronchogen has been studied predominantly in chronic obstructive bronchial models, Chonluten investigations have focused on age-associated involution of bronchial mucosa, oxidative stress in pulmonary epithelium, and the restoration of surfactant-producing cellular populations. The peptide is supplied as a lyophilized white powder for research use and is non-glycosylated, non-disulfide-bonded, and free of post-translational modifications, simplifying handling relative to larger regulatory peptides.

Interest in Chonluten has grown in the context of geroscience and respiratory aging research, where short peptide bioregulators are studied as tools for probing tissue-specific transcriptional regulation. AminoCore Research supplies Chonluten at ≥98% HPLC purity for laboratory investigation only; the compound is not approved for human therapeutic use in most jurisdictions and is offered strictly as a research reagent.

Chonluten (Thr-Glu-Asp, TED) is a synthetic short peptide bioregulator belonging to the Khavinson family of tissue-specific tripeptides. Like related compounds such as Bronchogen (Ala-Glu-Asp-Pro) and Vilon (Lys-Glu), Chonluten is hypothesised to act through epigenetic and gene-regulatory mechanisms in bronchial and alveolar epithelial cells, rather than via classical receptor-mediated signalling.

Direct DNA Interaction and Gene Expression

Research conducted by Khavinson and colleagues suggests that short peptides of this class can penetrate cell and nuclear membranes and interact directly with specific DNA promoter regions. The proposed mechanism involves sequence-specific binding of the tripeptide to double-stranded DNA in the major groove, with the Thr-Glu-Asp motif demonstrating affinity for promoters associated with bronchial epithelial differentiation, mucin synthesis regulation, and antioxidant defence pathways. This binding is hypothesised to modulate transcription factor accessibility and alter the expression of genes involved in mucociliary clearance and epithelial repair.

Bronchial Epithelial Normalisation

In preclinical bronchial mucosa models, Chonluten has been associated with normalisation of ciliated epithelial cell function, restoration of goblet cell distribution, and modulation of surfactant-related protein expression in alveolar type II cells. These effects suggest a role in restoring the structural and functional integrity of the respiratory epithelium following chronic inflammatory or oxidative insult.

Anti-Inflammatory and Immunomodulatory Pathways

Research suggests Chonluten may attenuate pro-inflammatory cytokine cascades within bronchial tissue, including modulation of TNF-alpha, IL-6, and IL-8 expression. The peptide has been associated with reduced neutrophil infiltration in models of chronic bronchitis and chronic obstructive pulmonary changes. By restoring local cytokine balance, Chonluten is hypothesised to support resolution of mucosal inflammation without immunosuppression.

Antioxidant and Cytoprotective Effects

Preclinical data indicate that Chonluten administration is associated with upregulation of endogenous antioxidant enzymes such as superoxide dismutase (SOD) and catalase within respiratory epithelium. This activity may protect bronchial cells from reactive oxygen species generated during chronic inflammation, smoke exposure, or aging.

Comparison with Related Bioregulators

While Bronchogen (Ala-Glu-Asp-Pro) is also a respiratory bioregulator, Chonluten's tripeptide structure (Thr-Glu-Asp) gives it a distinct DNA-binding profile and tissue-selective activity. Both peptides target bronchial epithelium, but research suggests Chonluten has stronger effects on mucociliary clearance and ciliated cell function, while Bronchogen has been more extensively studied for alveolar regeneration. This functional complementarity has led some research groups to investigate the two peptides in parallel within respiratory bioregulation models.

Geroprotective Activity

Like other Khavinson peptides, Chonluten has been associated with geroprotective effects in aged animal models, including normalisation of age-related changes in bronchial epithelium and improved respiratory function parameters. These effects align with the broader hypothesis that short peptide bioregulators can modulate cellular senescence pathways through epigenetic mechanisms.

Chonluten is a synthetic tripeptide bioregulator consisting of threonine, glutamic acid, and aspartic acid (Thr-Glu-Asp, TED). It belongs to the Khavinson family of short peptide bioregulators developed at the Saint Petersburg Institute of Bioregulation and Gerontology and is tissue-specific to bronchial and alveolar epithelium.

The tripeptide structure of Chonluten gives it several practical advantages as a research compound: high water solubility, relative stability in lyophilized form, and resistance to many proteolytic enzymes compared with longer peptides. The carboxylate-rich structure (two acidic residues — Glu and Asp) contributes to its proposed DNA-binding affinity through electrostatic interactions with the phosphate backbone and hydrogen bonding with nucleotide bases.

Researchers should note that Chonluten, like other short Khavinson peptides, is typically studied at microgram-per-kilogram dose ranges in animal models, reflecting its proposed gene-regulatory mechanism rather than receptor-saturation pharmacology. This distinguishes its handling requirements from larger peptide hormones and growth factors.

Chonluten is supplied as a sterile lyophilized white powder in sealed glass vials under inert atmosphere. Proper reconstitution and handling preserve peptide integrity and ensure reproducible results in research applications. As a small tripeptide without disulfide bridges, methionine, or tryptophan residues, Chonluten is comparatively stable to oxidative degradation, but standard short-peptide handling practices still apply.

Recommended reconstitution protocol:

1. Equilibrate the vial to room temperature for 20-30 minutes before opening to prevent moisture condensation on the lyophilized cake.
2. Briefly centrifuge the sealed vial at low speed to collect powder at the bottom.
3. Select reconstitution solvent: bacteriostatic water for injection (0.9% benzyl alcohol) or sterile sodium chloride 0.9% for short-term use. Sterile water for injection is suitable for immediate-use preparations.
4. Add solvent slowly along the inner wall of the vial. Typical reconstitution: 5 mg of Chonluten + 1 mL solvent = 5 mg/mL stock, or 5 mg + 2 mL = 2.5 mg/mL for lower-concentration aliquoting.
5. Do not shake or vortex. Gently swirl the vial until the powder is fully dissolved (typically <60 seconds). Aggressive agitation can promote aggregation and foaming of peptide solutions.
6. Inspect the solution: reconstituted Chonluten should appear clear and colorless with no visible particulates.
7. Aliquot the reconstituted stock into low-binding microtubes to minimize freeze-thaw cycles in subsequent experiments.

Compound-specific notes:

• Chonluten is highly water-soluble due to the polar Thr, Glu, and Asp side chains; DMSO is not required.
• Avoid contact with strongly acidic or alkaline buffers, which may catalyze hydrolysis of the peptide backbone.
• Working dilutions for cell culture are typically prepared at nanomolar to picomolar concentrations, consistent with the Khavinson peptide literature describing biological activity in the 10^-12 to 10^-9 M range.
• Use aseptic technique throughout; the bronchial mucosa research context often involves co-culture with bacterial-sensitive cell lines.

All handling should occur in a designated research laboratory environment using appropriate personal protective equipment. Chonluten is intended for in vitro and preclinical research use only.